Today, LanzaTech announced the signing of a new multi-year contract with TeselaGen Biotechnology, extending their relationship through 2025. The two companies have been collaborating since 2016 on the informatics behind high-throughput synthetic biology workflows. Over that time, LanzaTech has continued to experience rapid growth, showing the feasibility to synthesize more than 100 different molecules using its carbon-eating bacteria, and demonstrating the need for a significant scaleup of its R&D operations.
“Designing and optimizing biology is not easy, and we are in a race to recycle more carbon before it is too late. This collaboration with TeselaGen will extend our capabilities and help us achieve our goals”, said Dr. Sean Simpson Chief Scientific Officer and Co-founder at LanzaTech. “TeselaGen has developed one of the most advanced cloud-based solutions for designing, building, and optimizing complex biological workflows and products. We are enthusiastic about extending our collaboration with the TeselaGen team”, added Dr. Michael Köpke, Vice President Synthetic Biology at LanzaTech.
“LanzaTech has developed unique wet-lab capabilities, as well as some advanced bioinformatic solutions tailored for optimizing their anaerobic microbes. With input from LanzaTech, we have developed an operating system for biotechnology that can interoperate with existing infrastructure and services, facilitating the flow of information across various services, biotech vendors, external databases, algorithms, and automated equipment. This helps LanzaTech keep tight control of their biological design automation process, from start to finish. We want to enable the biotech industry to iterate faster, helping it reduce costs and time-to-market”, said Dr. Eduardo Abeliuk, Chief Executive Officer and Co-founder of TeselaGen.
“The ability to economically recycle poisonous greenhouse gas like carbon oxides into valuable products via a biological process is an amazing achievement. We are excited to continue helping this very talented team at LanzaTech push the limits of what’s possible through Synthetic Biology,” added Michael Fero, Chief Operating Officer and Co-founder of TeselaGen. “In particular, we look forward to bringing our recently published iterative machine learning approach to the task of making LanzaTech’s microbes even more efficient,” he added.